Poland· PL-100528584
Lunsumio
A mosunetuzumab product containing mosunetuzumabum, registered in Poland by Roche Registration GmbH. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Mosunetuzumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FX25 (mosunetuzumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Mosunetuzumab · ATC L01FX25
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Mosunetuzumabum
- Manufacturer
- Roche Registration GmbH
- Country
- Poland (PL)
- ATC code
- L01FX25
- ATC class
- Mosunetuzumab
- Defined daily dose
- 1.8 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin07613326108133
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mosunetuzumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumLunsumio 45 mgRoche Registration
- CzechiaLUNSUMIORoche Registration GmbH, Grenzach-Wyhlen
- SpainLUNSUMIO 45 MG SOLUCION INYECTABLERoche Registration Gmbh
- IcelandLunsumioRoche Registration GmbH*
- SwedenLunsumio 45 mg Injektionsvätska, lösningRoche Registration GmbH
- United StatesLunsumioGenentech, Inc.
- FinlandLunsumioOrifarm Oy
- Japanモスネツズマブ（遺伝子組換え）中外製薬
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lunsumio
- Liechtenstein · Lunsumio
- Norway · Lunsumio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6fbb9a43-7567-4a44-aa0d-2ca6767155d8 GET /v1/drugs/6fbb9a43-7567-4a44-aa0d-2ca6767155d8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "45 mg",
"packaging": "07613326108133 ¦ Rpz ¦ EU/1/22/1649/004 ¦ 164786\n1 fiol. 1 ml",
"substance": "Mosunetuzumabum 45 mg",
"common_name": "Mosunetuzumabum",
"pl_product_id": "100528584",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about mosunetuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.